Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Citation: Boominathan, MiRNA-based therapy for Chronic Myelogenous Leukemia (CML): MiRNA-217 eradicates CML leukemia stem cells via activation of p53, 8/October/2014, 7.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
Significance: This study suggests that tumor suppressor MiRNA-217, by decreasing the expression of its target gene, it may increase the expression of guardian of the genome p53; and decrease the expression of immortality gene telomerase. Given that p53 is the most mutated tumor suppressor gene in human cancer, pharmacological formulations encompassing “MiRNA-217 or its activators“ may be used to eliminate CML leukemia stem cells.